Company intelligence / Profile preview
Manhattan BioSolutions
- Ownership
- Private
- Development stage
- Other
Overview
Manhattan BioSolutions engineers next-generation antibody-drug conjugates and biologic immunotherapies using proprietary technologies inspired by natural immune mechanisms. Their lead programs target advanced solid and hematologic cancers. The company has established multiple academic collaborations and industry partnerships to advance its pipeline from discovery through early clinical development. Notably, they collaborate with Nascent Biotech on pritumumab-based ADCs targeting vimentin-positive tumors. Internal programs are primarily preclinical or early clinical stage.
- Therapeutic areas
- OncologyHematology
- Modalities
- Antibody-drug conjugates (ADCs)Monoclonal antibodies (mAbs)RNA-degrader proteins
- Industry
- Biotech
Drug pipeline
10 assets9 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Manhattan BioSolutions.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Manhattan BioSolutions.